| NCT04475523 | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | COMPLETED | PHASE1 | 2020-09-22 | 2023-05-19 | 2023-05-19 |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | RECRUITING | PHASE1, PHASE2 | 2020-07-06 | 2026-04-01 | 2026-04-01 |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | RECRUITING | PHASE1, PHASE2 | 2017-12-28 | 2026-10 | 2026-08 |
| NCT02674750 | Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations | COMPLETED | PHASE2 | 2016-07 | 2019-05-28 | 2019-05-28 |
| NCT02812875 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | COMPLETED | PHASE1 | 2016-05 | 2020-05-07 | 2020-05-07 |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | COMPLETED | PHASE1 | 2014-11 | 2019-05-31 | 2019-05-31 |
| NCT01908413 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | TERMINATED | PHASE1 | 2013-07 | 2015-11 | 2015-03 |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | COMPLETED | PHASE1 | 2012-12 | 2020-10-09 | 2020-10-09 |
| NCT01702285 | Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients | TERMINATED | PHASE1 | 2012-09 | 2012-12 | 2012-12 |
| NCT01384799 | Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer | COMPLETED | PHASE1 | 2011-11 | 2013-10 | 2013-09 |
| NCT01171924 | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors | COMPLETED | PHASE1 | 2010-07 | 2011-10 | 2011-10 |
| NCT00728793 | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2008-08 | 2010-04 | 2010-04 |